RainDance Technologies Names Kathy Ordoñez Chairman Of The Board Of Directors

Former Roche Molecular CEO and Quest Diagnostics SVP to help company capitalize on emergence of novel genomic and proteomic technologies for precision medicine applications

BILLERICA, Mass.--(BUSINESS WIRE)--RainDance Technologies, Inc., a genomics tools company dedicated to simplifying the analysis of complex genetic diseases, today announced the appointment of Kathy Ordoñez as Chairman of its Board of Directors. Ms. Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries, and has served on the RainDance Board of Directors since 2014, and as the Chair of the Board's Science and Innovation Committee.

"Kathy has contributed strongly to our Board leadership and business progress – helping to define our science and innovation priorities and to guide the direction of our product roadmap"

As Senior Vice President at Quest Diagnostics, Kathy Ordoñez was responsible for leading the company's businesses in diagnostic products, insurer services, clinical trials and healthcare information technology products and also led Research and Development. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann La-Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the application of Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.

"RainDance's proprietary droplet technology has tremendous potential for a wealth of applications in genetics and proteomics," said Ms. Ordoñez. "With an experienced leadership team, a growing customer base and one of the industry's most sensitive nucleic acid detection and monitoring platforms, RainDance has a strong foundation in place. I look forward to helping the company build on its success and realize its vision of making complex genetics simple for all scientists."

"Kathy has contributed strongly to our Board leadership and business progress – helping to define our science and innovation priorities and to guide the direction of our product roadmap," said Roopom Banerjee, President and CEO, RainDance Technologies. "As Chairman, she will play an even greater role in helping to craft our strategic direction as we scale our business and start to realize the potential for liquid biopsy and precision medicine."

About RainDance Technologies
RainDance Technologies is making complex genetics simple. The company's ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011. For more information, please visit www.RainDanceTech.com.

Stay Connected with RainDance Technologies – Complex Genetics Made Simple
RainDanceTech.com/Twitter | RainDanceTech.com/LinkedIn |RainDanceTech.com/Blog

The RainDrop Digital PCR System, ThunderBolts NGS System, and ThunderStorm NGS Content Enrichment System are for Research Use Only; not for use in diagnostic procedures.

RainDance Technologies, the RainDance Technologies logo, ThunderBolts, RainDrop, and ThunderStorm, are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.

Contacts

BlueChair Group
Pamela Mahoney, 408-674-6997
[email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.